Login
$HIND
$1.53 -$0.05 (3.16%) Close

$HIND 8-K SEC Filings

Filed On Filing
28 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Consulting Agreement (the “Agreement”) is made effective as of September 1, 2026 (the “Effective Date”), by and between Vyome Holdings, Inc., a Delaware corporation, with its principal place of business at Harvard Square, One Miffli...

25 Aug 2026 8-K: Results of Operations and Financial Condition

Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet

29 May 2026 8-K: Results of Operations and Financial Condition

Vyome has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1

29 Apr 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “VYOME HOLDINGS, INC.”, FILED IN THIS OFFICE ON THE TWENTY-FOURTH DAY OF ...

25 Feb 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Notes Purchase and Exchange Agreement (this “Agreement”) is entered into as of February 20, 2026 (the “Effective Date”) by and among (i) LiveChain, Inc., a Nevada corporation (“LICH”); (ii) LICH AI, Inc., a Delaware corporation and ...

13 Feb 2026 8-K: Regulation FD Disclosure

VT - 1953 in Treating Symptoms of Malignant Fungating Wounds (MFW) PHASE 2 IST STUDY RESULTS & NEXT STEPS © Vyome Holdings, Inc. February 2026

28 Jan 2026 8-K: Regulation FD Disclosure; Other Events

1 U.S. Market & Product Assessment and Valuation of VT - 1953 for the Treatment of Symptoms of Malignant Fungating Wounds H1 2026

23 Dec 2025 8-K: Entry into a Material Definitive Agreement

This letter of intent (this “LOI”) outlines the general terms and conditions of a prospective transaction (as further described herein, the “Transaction”) between LiveChain, Inc., a Delaware corporation (“LICH”), Remus Capital Series B I...

19 Nov 2025 8-K: Results of Operations and Financial Condition

Completed a streamlined Nasdaq listing, with a 100% common stock capital structure

30 Oct 2025 8-K: Submission of Matters to a Vote of Security Holders

On October 28, 2025, Vyome Holdings, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders. A total of 4,258,856 shares of common stock representing 77.52% of the aggregate shares outstanding and eligible to vote and constitu...

03 Oct 2025 8-K: Other Events

Launches business unit to create AI psychiatrist focused on reducing inflammation

02 Sep 2025 8-K: Other Events

The accompanying notes are an integral part of these consolidated financial statements.

20 Aug 2025 8-K: Entry into a Material Definitive Agreement; Changes in Registrant's Certifying Accountant

This AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT (this “Amendment”) is entered into as of August 20, 2025, by and between Vyome Holdings, Inc. (formerly known as ReShape Lifesciences, Inc.), a Delaware corporation (the “Company”), a...

19 Aug 2025 8-K: Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities +3 more

I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DESIGNATION OF “RESHAPE LIFESCIENCES INC.”, FILED IN THIS OFFICE ON THE FOURTEENTH...

11 Aug 2025 8-K: Submission of Matters to a Vote of Security Holders

On August 7, 2025, ReShape Lifesciences Inc. (the “Company”) reconvened its special meeting of stockholders (“Special Meeting”), which was partially adjourned on July 24, 2025.

25 Jul 2025 8-K: Submission of Matters to a Vote of Security Holders

ReShape Lifesciences Inc. (the “Company”) held a special meeting of stockholders on July 24, 2025 (the “Special Meeting”). A total of 1,482,585 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), consti...

15 Jul 2025 8-K: Regulation FD Disclosure

Vyome A US-India healthcare platform with clinical-stage immuno-inflammation assets PENDING MERGER $RSLS TO $HIND CORPORATE PRESENTATION JULY 2025

03 Jul 2025 8-K: Entry into a Material Definitive Agreement

FOR VALUE RECEIVED, Vyome Therapeutics, Inc., a Delaware corporation (“Vyome”), promises to pay to the order of ReShape Lifesciences Inc., a Delaware corporation and its successors and assigns (“ReShape”), in lawful money of the United S...

18 Jun 2025 8-K: Other Events

As previously disclosed, on May 28, 2025, ReShape Lifesciences Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company its securities are subject to d...

12 Jun 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Subject to the terms and conditions herein (this “Agreement”), ReShape Lifesciences Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $2,636,510 of shares (each a "...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support